ONCOLOGIST

ONCOLOGIST Journal

publication venue for

Treatment of locally advanced pancreatic cancer using localized trans-arterial micro perfusion of gemcitabine: combined analysis of RR1 and RR2 2024
Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma 2024
Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials 2023
Using Tumor-Informed Circulating Tumor DNA (ctDNA)-Based Testing for Patients with Anal Squamous Cell Carcinoma 2022
Caregiver-Oncologist Prognostic Concordance, Caregiver Mastery, and Caregiver Psychological Health and Quality of Life. 26:310-317. 2021
A Phase I Trial of Trametinib in Combination with Sorafenib in Patients with Advanced Hepatocellular Cancer. 25:E1893-E1899. 2020
Real-WorldTreatment Patterns andProgression-FreeSurvival Associated with Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies forALK plus Non-SmallCell Lung Cancer. 25:867-877. 2020
A PhaseII,Single-Arm,Open-Label, Bayesian Adaptive Efficacy and Safety Study ofPBI-05204 in Patients with StageIVMetastatic Pancreatic Adenocarcinoma. 25:E1446-E1450. 2020
Surgery Versus Surveillance for Well-Differentiated, Nonfunctional Pancreatic Neuroendocrine Tumors: An 11-Year Analysis of the National Cancer Database. 25:E276-E283. 2019
A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial 2019
A Phase Ib, Open-Label Study of Dalantercept, an Activin Receptor-Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma. 24:161-+. 2019
Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression. 22:3-11. 2017
A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only. 21:279-280. 2016
Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer. 20:1298-1303. 2015
A Randomized Phase II Study of Carboplatin With Weekly or Every-3-Week Nanoparticle Albumin-Bound Paclitaxel (Abraxane) in Patients With Extensive-Stage Small Cell Lung Cancer. 20:105-106. 2015
Tolerability, Efficacy, and Safety of Pegylated Liposomal Doxorubicin in Combination with Carboplatin Versus Gemcitabine-Carboplatin for the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer: A Systematic Review 2010
Considerations for second-line therapy of non-small cell lung cancer. 13:28-36. 2008
Gefitinib in Advanced Non-Small Cell Lung Cancer: Does It Deserve a Second Chance?. 13:933-944. 2008
Combined modality therapy for stage III non-small cell lung cancer. 11:809-823. 2006
Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: A preliminary report of a phase I dose escalation trial from the Carolina Conformal Therapy Consortium. 6:20-24. 2001
Single-agent paclitaxel in the treatment of advanced non-small cell lung cancer. 1999

category

ONCOLOGY Web of Science Category

International Standard Serial Number (ISSN)

1083-7159

Electronic International Standard Serial Number (EISSN)

1549-490X

journal abbreviation

ONCOLOGIST
Oncologist